Abbott Laboratories to pay $385-million to settle Sturgis baby formula plant case

Abbott Laboratories will pay $385 million to settle allegations of false claims related to infant formula manufacturing. The DOJ claims Abbott submitted false claims to federal programs from 2018 to 2022, while Abbott denies wrongdoing. The settlement resolves issues linked to a 2022 recall and plant shutdown that worsened a national formula shortage.

Abbott Laboratories will pay $385 million to resolve allegations of submitting false claims to federal and state programs. The U.S. Attorney's office claimed Abbott failed to meet safety standards for infant formula and nutritional therapy products between 2018 and 2022. The settlement includes $348.7 million to the U.S. and $36.3 million to certain states.

Abbott Laboratories will pay $385 million to settle a lawsuit over its 2022 plant closure and formula recall. The FDA and CDC investigated the recall but found no definitive link to infant deaths. The settlement resolves federal and state claims.

Abbott Laboratories agreed to a $385M settlement with the U.S. DOJ over unsanitary conditions at its Sturgis baby formula factory, which led to a 2022 recall and national shortage. The settlement resolves claims of selling contaminated formula through government programs. Three whistleblowers will receive $69M. Abbott denies liability and faults.

Abbott Laboratories will pay $384 million to settle claims it sold contaminated infant formula through federal and state programs. The DOJ accused Abbott of manufacturing products in unsanitary conditions, which the company denies. The settlement includes payments to the U.S. government, states, and whistleblowers. Abbott recalled its Similac, Alimentum, and EleCare formulas in 2022.

Abbott Laboratories agreed to pay $385m to settle US government claims related to its 2022 infant formula recall. The settlement resolves DOJ and state legal cases, with Abbott denying fault. The recall caused a US formula shortage. Abbott will pay $348.7m to the federal government and $36.3m to states. The DOJ accused Abbott of non-compliance and unsafe production practices. Abbott maintains its products were safe, citing negative tests for Cronobacter sakazakii.